External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ESMO IO 2025

We will be contributing to topics related to
-
05:15 PM
Duration 75mins London, United Kingdom
IMreal Cohort 5: interim analysis of effectiveness and safety outcomes in metastatic PD-L1 high NSCLC patients treated with atezolizumab in routine clinical practice
JOSE LUIS PEREZ GRACIA, Nicolas Girard, Sanjay Popat, Stefaniya Shoshkova, Sunil Sharma
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 75mins London, United Kingdom
Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Updated overall survival (OS) analyses of the Phase 3 IMforte trial
Bhatt Kamalnayan, Debasis Chakrabarti, George Cai, Hossein Borghaei, Juan Vazquez Limon, Katarzyna Stencel, Konstantinos Syrigos, LUIS PAZ-ARES RODRIGUEZ, Lisa Lin, Margarita Majem Tarruella, Martin Reck, Mehmet Artac, Roy Herbst, Solange Peters, Stephen Liu, Vaikunth Cuchelkar, Vilma Graupner
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon